Document:

Prepared by MERRILL CORPORATION

QuickLinks
 -- Click here to rapidly navigate through this document

Exhibit 10.21  

 
 

WARRANT PURCHASE AGREEMENT    
  

    THIS WARRANT PURCHASE AGREEMENT ("Agreement") is made as of March 16, 2001 (the "Effective Date"), by and between SeeBeyond Technology Corporation, a
California corporation (the "Company"), and General Motors Corporation, a Delaware corporation ("GM"). 

    WHEREAS,
GM intends to purchase a warrant from the Company, which warrant will be exercisable for shares of the Company's common stock; and 

    WHEREAS,
the parties hereto wish to provide for the sale and issuance of such warrant in consideration for services rendered and to be rendered to the Company by GM as contemplated by
Section 3 of the Warrant; 

    NOW,
THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS: 

    1.  Issuance of the Warrant.  The Company hereby sells and issues to GM a warrant (the "Warrant") to
purchase shares of the Company's common stock (collectively, the "Common Stock") as set forth therein in consideration for services rendered and to be rendered to the Company by GM as contemplated by
Section 3 of the Warrant. The Warrant shall be in the form attached hereto as Exhibit A. 

    2.  Representations and Warranties of the Company.  In connection with the transactions provided for
herein, the Company hereby represents and warrants to GM that: 

    2.1  Organization, Good Standing, and Qualification.  The Company is a corporation duly organized,
validly existing, and in good standing under the laws of the State of California and has all requisite corporate power and authority to carry on its business as now conducted. The Company is duly
qualified to transact business and is in good standing in each jurisdiction in which the failure so to qualify would have a material adverse effect on its business or properties. 

    2.2  Authorization.  All corporate action on the part of the Company, its officers, directors and
stockholders necessary for the authorization, execution and delivery of this Agreement, the performance of all obligations of the Company hereunder, and the authorization, issuance (or reservation for
issuance), and delivery of the Warrant and the Common Stock issuable upon exercise of the Warrant has been taken or will be taken prior to the Closing. 

    2.3  Valid Issuance of Common Stock.  

    (a) The
Warrant, when issued, sold and delivered in accordance with the terms hereof for the consideration expressed herein, will be duly and validly issued, fully paid
and nonassessable, will be delivered to GM free and clear of all liens, pledges, claims, encumbrances, security interest or other restrictions, except for restrictions on transfer contemplated herein
or imposed to ensure compliance with the Securities Act of 1933, as amended, and, based on the representations of GM in this Agreement, will be issued in compliance with all applicable federal and
state securities laws. 

    (b) The
Common Stock, when issued, sold, and delivered in accordance with the terms of the Warrant for the consideration expressed therein, will be duly and validly
issued, fully paid, and nonassessable, free and clear of all liens, pledges, claims, encumbrances, security interest or other restrictions, except for restrictions on transfer contemplated herein or
imposed to ensure compliance with the Securities Act of 1933, as amended, and, based upon the representations of GM in this Agreement, will be issued in compliance with all applicable federal and
state securities laws. 

    2.4  No Conflicts.  The execution, delivery and performance by the Company of this Agreement and the
Warrant will not result in any violation of and will not conflict with, or result in a breach of any of the terms of, or constitute a default under, the Company's Amended and 

 

Restated Articles of Incorporation or Bylaws, or any provision of any material mortgage, pledge, lien or encumbrance upon any of the properties or assets of the Company. 

    2.5  Consents.  No consent, approval, qualification, order or authorization of, or filing with, any
governmental authority or any third party is required in connection with the Company's valid execution,
delivery or performance of this Agreement, or the offer, sale or issuance of the Warrant or the Common Stock issuable upon exercise of the Warrant, except filings required pursuant to applicable
federal and state securities laws and blue sky laws. 

    2.6  Litigation.  Except as otherwise disclosed in the Quarterly Report on Form 10-Q (the
"Form 10-Q") filed by the Company with the Securities and Exchange Commission (the "SEC") on November 14, 2000, there are no actions, suits or proceedings pending, or to the Company's
knowledge, threatened, to which the Company is a party or its property is subject, which is reasonably likely to result in any material adverse change in the business or financial condition of the
Company, and none which questions the validity of this Agreement or the Warrant or any action taken or to be taken in connection herewith and therewith or the right of the Company to enter into such
agreements. 

    2.7  Capitalization.  As of the date hereof, the Company's authorized capital stock consists of (a)
200,000,000 shares of Common Stock, and (b) 10,000,000 shares of undesignated Preferred Stock. As of March 9, 2000, 70,392,922 shares of Common Stock were issued and outstanding, and no shares of
Preferred Stock were issued and outstanding. All the aforesaid issued and outstanding shares are duly authorized, validly issued, fully paid and nonassessable. 

    2.8  Absence of Certain Changes.  Since the date of filing of the Form 10-Q by the Company, there
has not been any event or condition which has materially and adversely affected the Company's assets, properties, financial condition, operating results or business (as such business is presently
conducted). 

    2.9  Intellectual Property Rights.  To the Company's knowledge, the Company has all franchises, permits,
licenses, and other similar authority necessary for the conduct of its business, the lack of which would materially and adversely affect the Company's assets, properties, financial condition,
operating results or business (as such business is presently conducted) (the "Intellectual Property") and none of such franchises, permits, licenses or similar authority which are material to the
conduct of the Company's business will expire (or may not be renewed by the Company without undue burden or expense) within three (3) years following the Effective Date. The Company is not in default
in any material respect under any of such franchises, permits, licenses or other similar authority. The Company has sufficient title and ownership of all patents, patent rights, trademarks, trademark
rights, trade names, trade name rights and copyrights necessary to conduct its business as now being conducted, without conflict with or infringement upon any valid rights of others and the lack of
which would materially and adversely affect the operations or financial condition of the Company. The Company is not aware of any third party which is infringing or violating any of the intellectual
Property of the Company. 

    2.10  Compliance with Laws.  To its knowledge, the Company is not in violation of any applicable statute,
law or regulation, the violation of which would be reasonably likely to have a material adverse effect on the financial condition or operations of the Company. 

    2.11  Financial Statements.  The Company's financial statements contained in the Form 10-Q (i) are
in accordance with the books and records of the Company, and (ii) have been prepared in accordance
with generally accepted accounting principles applied on a consistent basis, subject, in the case of the unaudited financial statements, to the absence of footnote disclosures and to changes resulting
from year end audit adjustments. 

2

 

    2.12  Disclosure.  Neither this Agreement nor the Warrant, when taken as a whole, contains any untrue
statement of a material fact or omits to state a material fact necessary to make the statements therein not misleading. 

    3.  Representations and Warranties of GM.  In connection with the transactions provided for herein, GM
hereby represents and warrants to the Company that: 

    3.1  Authorization.  This Agreement constitutes GM's valid and legally binding obligation, enforceable in
accordance with its terms. 

    3.2  Purchase Entirely for Own Account.  GM acknowledges that this Agreement is made with GM in reliance
upon GM's representation to the Company that the Warrant and the Common Stock issuable upon exercise of the Warrant (collectively, the "Securities") will be acquired for investment for GM's own
account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that GM has no present intention of selling, granting any participation in, or otherwise
distributing the same. By executing this Agreement, GM further represents that it does not have any contract, undertaking, agreement, or arrangement with any person to sell, transfer, or grant
participations to such person or to any third person, with respect to the Securities. GM represents that it has full power and authority to enter into this Agreement. 

    3.3  Disclosure of Information.  GM acknowledges that it has received all the information it considers
necessary or appropriate for deciding whether to acquire the Securities. GM further represents that it has had an opportunity to ask questions and receive answers from the Company regarding the terms
and conditions of the offering of the Securities. 

    3.4  Investment Experience.  GM is an investor in securities of companies in the technology business and
acknowledges that it can bear the economic risk of its investment, and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the
investment in the Securities. GM also represents it has not been organized solely for the purpose of acquiring the Securities. 

    3.5  Accredited Investor.  GM is an "accredited investor" within the meaning of Rule 501 of Regulation D
of the SEC, as presently in effect. 

    3.6  Restricted Securities.  GM understands that the Securities are characterized as "restricted
securities" under the federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations
such securities may be resold without registration under the Securities Act of 1933, as amended (the "Act"), only in certain limited circumstances. In this connection, GM represents that it is
familiar with SEC Rule 144, as presently in effect, and understands the resale limitations imposed thereby and by the Act. 

    3.7  Further Limitations on Disposition.  Without in any way limiting the representations set forth
above, GM further agrees not to make any disposition of all or any portion of the Securities until either: 

    (a) There
is then in effect a Registration Statement under the Act covering such proposed disposition and such disposition is made in accordance with such Registration
Statement; or 

    (b) (i)
GM shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances surrounding
the proposed disposition, and (ii) if reasonably requested by the Company, GM shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such disposition
will not require registration of such shares under the Act. 

3

 

    3.8  Legend.  It is understood that the Securities shall bear the following legend: 

    "These
securities have not been registered under the Securities Act of 1933. They may not be sold, offered for sale, pledged, hypothecated, or otherwise transferred except pursuant to
an effective registration statement under the Securities Act of 1933 or an opinion of counsel satisfactory to the Company that registration is not required under such Act or unless sold pursuant to
Rule 144 under such Act." 

    4.  California Corporate Securities Law.  THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS
AGREEMENT HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION FOR
SUCH SECURITIES PRIOR TO SUCH QUALIFICATION IS UNLAWFUL, UNLESS THE
SALE OF SECURITIES IS EXEMPT FROM QUALIFICATION BY SECTION 25100, 25102 OR 25105 OF THE CALIFORNIA CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY CONDITIONED UPON SUCH
QUALIFICATION BEING OBTAINED, UNLESS THE SALE IS SO EXEMPT. 

    5.  Miscellaneous.  

    5.1  Successors and Assigns.  Except as otherwise provided herein, the terms and conditions of this
Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party
other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this
Agreement. Except in accordance with the Warrant, the Warrant cannot be assigned by GM without the express written consent of the Company, except when such assignment is to an affiliate of GM. 

    5.2  Arbitration.  

    (a) In
the event of any dispute arising hereunder with respect to a breach of any representation and warranty or other provision hereof, or with respect to the
transactions contemplated hereby, the Company and GM shall attempt in good faith for thirty (30) days to agree upon the rights of the respective parties with respect to such dispute. If the Company
and GM should so agree, a memorandum setting forth such agreement shall be prepared and signed by such parties and shall be binding upon such parties and each other or transferee of any of the
Securities. 

    (b) If
no such agreement can be reached after good faith negotiation, either the Company or GM may, by written notice to the other, demand arbitration of the matter
unless the amount of the damage or loss is at issue in pending litigation with a third party, in which event arbitration shall not be commenced until such amount is ascertained or such parties agree
to arbitration, and in either such event the matter shall be settled by arbitration conducted by three (3) arbitrators. Within fifteen (15) days after such written notice is sent, the Company and GM
shall each select one (1) arbitrator, and the two (2) arbitrators so selected shall select a third arbitrator. The decision of the arbitrators as to the validity and amount of any claim shall be
binding and conclusive upon the Company and GM or transferee of any of the Securities. 

    (c) Judgment
upon any award rendered by the arbitrators may be entered in any court having jurisdiction; however, the parties hereto agree to submit to the jurisdiction
of the federal and state courts of the State of California with respect to the rendering of any such judgment. Any such arbitration shall be held in Los Angeles County, California under the commercial
rules then in effect of the American Arbitration Association. 

4

 

    5.3  Governing Law.  This Agreement shall be governed by and construed under the laws of the State of
California as applied to agreements among California residents, made and to be performed entirely within the State of California. 

    5.4  Counterparts.  This Agreement may be executed in counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. 

    5.5  Titles and Subtitles.  The titles and subtitles used in this Agreement are used for convenience only
and are not to be considered in construing or interpreting this Agreement. 

    5.6  Notices.  Unless otherwise provided, any notice required or permitted under this Agreement shall be
given in writing and shall be deemed effectively given upon personal delivery to the party to be notified, by delivery by confirmed facsimile or upon deposit with the United States Post Office, by
registered or certified mail, postage prepaid and addressed to such party at the address set forth below, or at such other address as such party may designate by ten (10) days' advance written notice
to the other parties. 

If
to the Company: 

SeeBeyond
Technology Corporation

404 E. Huntington Drive

Monrovia, CA 91016

Attn.: Chief Executive Officer

Facsimile: 626-471-6103 

If
to GM: 

General
Motors Corporation

767 Fifth Avenue, 14th Floor

New York, NY 10153

Attn: Treasurer

Facsimile: 212-418-3630 

With
a copy to: 

General
Motors Legal Staff

3031 West Grand Boulevard

Detroit, MI 48202

Mailcode: 482-208-870

Attn: Karen Merkle

Facsimile: 313-974-1688 

    5.7  Finder's Fee.  Each party represents that it neither is or will be obligated for any finder's fee or
commission in connection with this transaction. GM agrees to indemnify and to hold harmless the Company from any liability for any commission or compensation in the nature of a finder's fee (and the
costs and expenses of defending against such liability or asserted liability) for which GM or any of its officers, partners, employees, or representatives is responsible. 

    The
Company agrees to indemnify and hold harmless GM from any liability for any commission or compensation in the nature of a finder's fee (and the costs and expenses of defending
against such liability or asserted liability) for which the Company or any of its officers, employees, or representatives is responsible. 

    5.8  Expenses.  If any action at law or in equity is necessary to enforce or interpret the terms of this
Agreement, the prevailing party shall be entitled to reasonable attorneys' fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 

5

 

    5.9  Reservation of Shares.  The Company shall reserve and keep available at all times, free of
preemptive rights, the full number of shares of Common Stock issuable upon exercise of the Warrant. 

    5.10  Entire Agreement; Amendments and Waivers.  This Agreement the Warrant, and the Registration Rights
Agreement (as amended per the terms of Section 9 of the Warrant), constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof.
Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), with
the written consent of the Company and GM. Any waiver or amendment effected in accordance with this Section shall be binding upon GM, each holder of any securities purchased under this
Agreement at
the time outstanding (including securities into which such securities have been converted), each future holder of all such securities, and the Company. 

    5.11  Severability.  If one or more provisions of this Agreement are held to be unenforceable under
applicable law, such provision shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance
with its terms. 

[THE
REMAINDER OF THIS PAGE LEFT INTENTIONALLY BLANK] 

6

 

    IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written. 

	 	 	 	 	SEEBEYOND TECHNOLOGY CORPORATION
	

 	
 	

 	
 	

By:	
 	

/s/ JAMES DEMETRIADES     
 James Demetriades

Chief Executive Officer
	

 	
 	

Address:	
 	

404 E. Huntington Drive

Monrovia, CA 91016
	

 	
 	

 	
 	

 	
 	

 
	

 	
 	

 	
 	

GENERAL MOTORS CORPORATION
	

 	
 	

 	
 	

By:	
 	

/s/ RALPH SZYGENDA     

	 	 	 	 	Name:	 	Ralph Szygenda

	 	 	 	 	Title:	 	Group Vice President and CIO

	

 	
 	

Address:	
 	

 	
 	

 
	

 	
 	

 	
 	

 	
 	

 
	

 	
 	

 	
 	

 	
 	

 
	SIGNATURE PAGE TO SEEBEYOND TECHNOLOGY CORPORATION

WARRANT PURCHASE AGREEMENT
	

 	
 	

 	
 	

 	
 	

 

7

 
 

EXHIBIT A    
  

THIS
WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE
TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED UNDER SUCH
ACT OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SUCH ACT. 

Void
after

March 16, 2006 

SEEBEYOND TECHNOLOGY CORPORATION
  WARRANT TO PURCHASE SHARES OF COMMON STOCK  

    This Warrant is issued to General Motors Corporation, a Delaware corporation ("GM"), by SeeBeyond Technology Corporation, a California corporation (the
"Company"), on March 16, 2001 (the "Warrant Issue Date"). This Warrant is issued pursuant to the terms of that certain Warrant Purchase Agreement (the "Purchase Agreement") dated as of March 16, 2001. 

    1.  Purchase of Shares.  Subject to the terms and conditions hereinafter set forth and set forth in the
Purchase Agreement, the holder of this Warrant is entitled, upon surrender of this Warrant at the principal office of the Company (or at such other place as the Company shall notify the holder hereof
in writing), to purchase from the Company up to 625,000 fully paid and nonassessable shares of the Common Stock of the Company, as more fully described below. The number of shares of Common Stock
issuable pursuant to this Section 1 (the "Shares") shall be subject to adjustment pursuant to Section 8 hereof. 

    2.  Purchase Price.  The per share purchase price for the Shares (the "Exercise Price") shall be $11.34.
The Exercise Price shall be adjusted from time to time pursuant to Section 8 hereof. 

    3.  Exercise Period.

    (a) This
Warrant may be exercised at the sole discretion of GM (subject to the conditions set forth herein) as to such number of Shares as is determined in accordance
with Section 3(b) hereof; and this Warrant shall remain so exercisable with respect to such Shares until the earliest to occur of (i) 5:00 p.m. (California time) on March 16, 2006, or (ii)
subject to Section 11 hereof, the date of the closing of the transaction contemplated by an agreement (A) to sell or transfer all or substantially all of the Company's assets in an arm's-length
transaction to another entity that is not an "affiliate" of the Company as "affiliate" is defined in Rule 405 of the Securities Act of 1933, as amended (the "Securities Act") or (B) pursuant to which
the Company is to be acquired by another entity that is not an affiliate of the Company as "affiliate" is defined in Rule 405 of the Securities Act by means of any transaction or series of related
transactions (including, without limitation, any reorganization, merger or consolidation) that results in the transfer of fifty percent (50%) or more of the outstanding voting power of the Company to
persons or entities that were not shareholders of the Company prior to such transaction. 

    (b) Starting
on the date hereof, this Warrant shall be exercisable for 175,000 Shares of the Company's Common Stock. As to the additional 450,000 Shares subject to this
Warrant, the holder of this Warrant understands that this Warrant shall become exercisable for (i)(A) 87,500 Shares of the Company's Common Stock on the date that is six (6) months from the date
hereof, (B) 87,500 Shares of the Company's Common Stock on the date that is twelve (12) months from the date hereof, (C) 100,000 Shares of the Company's Common Stock on the date that is eighteen (18)
months from the date hereof, (D) 100,000 Shares of the Company's Common Stock on the date that is twenty-four (24) months from the date hereof, (E) 37,500 Shares of the Company's Common Stock on the
date that is thirty (30) months from the date hereof, and (F) 37,500 Shares 

 

of the Company's Common Stock on the date that is thirty-six (36) months from the date hereof (each such date being referred to as a "Date"), and (ii) subject, in each instance, to the achievement of
the milestones which correspond to such Date as set forth in a vesting schedule to be agreed upon by the Company and GM. 

    4.  Method of Exercise.  While this Warrant remains outstanding and exercisable in accordance with
Section 3 above, the holder may exercise, in whole or in part, the purchase rights evidenced hereby. Such exercise shall be effected by: 

     (i) the
surrender of the Warrant, together with a duly executed copy of the form of subscription attached hereto, to the Secretary of the Company at its principal
offices; and 

    (ii) the
payment to the Company of an amount equal to the aggregate Exercise Price for the number of Shares being purchased. 

    5.  Net Exercise.  In lieu of cash exercising this Warrant, the holder of this Warrant may elect to
receive shares equal to the value of this Warrant (or the portion thereof being canceled) by surrender of this Warrant at the principal office of the Company together with notice of such election, in
which event the Company shall issue to the holder hereof a number of shares of Common Stock computed using the following formula: 

	 	 	Y (A - B)
	 	 	

	X =	 	A

	Where	 
	

X —	

The number of shares of Common Stock to be issued to the holder of this Warrant.
	

Y —	

The number of shares of Common Stock as to which this Warrant is being exercised.
	

A —	

The Fair Market Value (as defined herein) of one share of the Company's Common Stock.
	

B —	

The Exercise Price (as adjusted to the date of such calculations).

    For
purposes of this Section 5 and Section 2 hereof, the fair market value of one share of Common Stock shall mean the average of the closing bid and asked prices of the
Common Stock quoted in the over-the-counter market in which the Common Stock is traded or the closing price quoted on any stock exchange or nation market system (i.e., the Nasdaq National
Market) on which the Common Stock is listed, whichever is applicable, as published in the Western Edition of The Wall Street Journal for the ten (10)
trading days prior to the date of determination of fair market value. If the Common Stock is not traded on the over-the-counter market or on an exchange, the fair market value shall be the price per
share as shall be determined in good faith by the Company's Board of Directors. 

    6.  Certificates for Shares.  Upon the exercise of the purchase rights evidenced by this Warrant, one or
more certificates for the number of Shares so purchased shall be issued as soon as practicable thereafter, and in any event within twenty (20) days of the delivery of the subscription notice. 

    7.  Issuance of Shares.  The Company covenants that the Shares, when issued pursuant to the exercise of
this Warrant, will be duly and validly issued, fully paid and nonassessable and free from all taxes, liens, and charges with respect to the issuance thereof. 

2

 

    8.  Adjustment of Exercise Price and Number of Shares.  The number of and kind of securities purchasable
upon exercise of this Warrant and the Exercise Price shall be subject to adjustment from time to time as follows: 

    (a) Subdivisions, Combinations and Other Issuances.  If the Company shall at any time prior to the
expiration of this Warrant subdivide its Common Stock, by split-up or otherwise, or combine its Common Stock, or issue additional shares of its Common Stock or Common Stock as a dividend with respect
to any shares of its Common Stock, the number of Shares issuable on the exercise of this Warrant shall forthwith be proportionately increased in the case of a subdivision or stock dividend, or
proportionately decreased in the case of a combination. Appropriate adjustments shall also be made to the purchase price payable per share, but the aggregate purchase price payable for the total
number of Shares purchasable under this Warrant (as adjusted) shall remain the same. Any adjustment under this Section 8(a) shall become effective at the close of business on the date the
subdivision or combination becomes effective, or as of the record date of such dividend, or in the event that no record date is fixed, upon the making of such dividend. 

    (b) Reclassification, Reorganization and Consolidation.  In case of any reclassification, capital
reorganization, or change in the Common Stock of the Company (other than as a result of a subdivision, combination, or stock dividend provided for in Section 8(a) above), then, as a condition
of such reclassification, reorganization, or change, lawful provision shall be made, and duly executed documents evidencing the same from the Company or its successor shall be delivered to the holder
of this Warrant, so that the holder of this Warrant shall have the right at any time prior to the expiration of this Warrant to purchase, at a total price equal to that payable upon the exercise of
this Warrant, the kind and amount of shares of stock and other securities and property receivable in connection with such reclassification, reorganization, or change by a holder of the same number of
shares of Common Stock as were purchasable by the holder of this Warrant immediately prior to such reclassification, reorganization, or change. In any such case appropriate provisions shall be made
with respect to the rights and interest of the holder of this Warrant so that the provisions hereof shall thereafter be applicable with respect to any shares of stock or other securities and property
deliverable upon exercise hereof, and appropriate adjustments shall be made to the purchase price per share payable hereunder, provided the aggregate purchase price shall remain the same. 

    (c) Adjustment to Exercise Price in Certain Events.  If, prior to the date this Warrant is exercisable as
to all of the Shares, the Company (i) issues and sells shares of its Common Stock in a public offering in which shares of Common Stock are registered pursuant to the Securities Act, (ii) issues and
sells shares of its Common Stock in a private placement financing transaction resulting in proceeds to the Company of at least $10.0 million, or (iii) issues a warrant to purchase at least 100,000
shares of Common Stock to a strategic commercial partner, and the per share price paid by investors in such transaction (or the exercise price of the warrant, as the case may be) is less than the
Exercise Price (as adjusted for stock splits, if any, pursuant to Section 8 hereof) of this Warrant, then the Exercise Price as to the unexercised portion of this Warrant shall automatically
become such lower price per share. 

    (d) Notice of Adjustment.  When any adjustment is required to be made in the number or kind of shares
purchasable upon exercise of the Warrant, or in the Exercise Price, the Company shall promptly notify the holder of such event and of the number of shares of Common Stock or other securities or
property thereafter purchasable upon exercise of this Warrant. 

    9.  Registration Rights.  The Company shall effectuate, simultaneous with the execution of this Warrant
and the Purchase Agreement, an amendment of that certain Registration Rights Agreement dated as of May 8, 1998 (the "Rights Agreement") by and among the Company and certain of its 

3

 

investors so that the Shares issuable upon exercise of this Warrant shall have registration rights which are pari passu to the rights granted in
Section 6 ("Company Registrations") and Section 8 ("Registration on Form S-3") of the Rights Agreement to investors which are a party thereto. 

    10. Co-Sale Right.

    (a) Subject
to subsection 10(b) below, in the event that the Company proposes to sell a number of shares of its Common Stock which is more than fifteen percent (15%) of
the then-outstanding shares of Common Stock of the Company for cash in a public offering in which shares of Common Stock are registered pursuant to the Securities Act or in a private placement
financing transaction, the Company shall deliver to GM a written notice describing the proposed sale (the "Proposed Sale") stating: (i) the identity of the proposed purchaser(s), if applicable, (ii)
the number of shares proposed to be offered by the Company (the "Offered Shares"), and (iii) the cash price at which the Company proposes to transfer the Offered Shares (the "Offered Price"). In such
event, GM shall have the right to sell a number of Shares held by GM which have been acquired solely upon exercise of this Warrant and the number of Offered Shares to be sold by the Company shall be
reduced on a share for share basis. In no event shall the number of Shares to be sold by GM exceed the number of shares sold by the Company in such a transaction. 

    (b) The
rights granted in Section 10(a) shall not apply to any of the following transactions: (A) the acquisition of the Company by another entity by means of
any transaction or series of related transactions (including, without limitation, any reorganization, merger or consolidation); (B) a sale of all or substantially all of the assets of the Company; or
(C) any issuance of shares pursuant to an employee benefit plan, stock option plan or employee stock purchase plan. 

    (c) The
rights granted to GM in this Section 10 are expressly subject to (i) the Company's ability to fully comply with federal and state securities laws, and
(ii) in the event that the Proposed Sale involves an underwritten public offering, the discretion of the underwriters of such offering as set forth in Section 6(b) of the Rights Agreement. 

    11. Change of Control of the Company.  If at any time the Company proposes to merge or consolidate with
or into any other corporation, effect any reorganization, or sell or convey all or substantially all of its assets to any other entity, then, as a condition of such reorganization, consolidation,
merger, sale or conveyance, the Company or its successor, as the case may be, shall enter into a supplemental agreement to make lawful and adequate provision whereby the Holder shall have the right to
receive, upon exercise of the Warrant, the kind and amount of equity securities which would have been received upon such reorganization, consolidation, merger, sale or conveyance by a holder of a
number of shares of common stock equal to the number of shares issuable upon exercise of the Warrant immediately prior to such reorganization, consolidation, merger, sale or conveyance. If the
property to be received upon such reorganization, consolidation, merger, sale or conveyance is not equity securities, the Company shall give the Holder of this Warrant ten (10) days prior written
notice of the proposed closing date of such transaction, and if this Warrant has not been exercised by or on the closing date of such transaction, it shall terminate. 

    12. No Fractional Shares or Scrip.  No fractional shares or scrip representing fractional shares shall be
issued upon the exercise of this Warrant, but in lieu of such fractional shares the Company shall make a cash payment therefor on the basis of the Exercise Price then in effect. 

    13. No Stockholder Rights.  Prior to exercise of this Warrant, the holder shall not be entitled to any
rights of a stockholder with respect to the Shares, including (without limitation) the right to vote such Shares, receive dividends or other distributions thereon, exercise preemptive rights or be
notified of stockholder meetings, and such holder shall not be entitled to any notice or other communication concerning the business or affairs of the Company. 

4

 

    14. Successors and Assigns.  The terms and provisions of this Warrant and the Purchase Agreement shall
inure to the benefit of, and be binding upon, the Company its successors and assigns. This Warrant cannot be assigned by GM without the express written consent of the Company. Notwithstanding the
foregoing, this Warrant may be assigned, sold or otherwise transferred to an affiliate of GM, and such assignment, sale or transfer shall not require the consent of the Company so long as such
assignment, sale or transfer complies with applicable laws, rules and regulations. In the event of a merger or acquisition in which the Company is not the surviving entity, the Company shall obtain
written confirmation from the successor entity as to the valid and binding nature of this Warrant on such successor entity. Notwithstanding the foregoing, this Warrant may be pledged by GM in
connection with a hedging transaction not involving the Company's stock without the prior written consent of the Company, so long as such transaction and pledge complies with applicable laws, rules
and regulations. 

    15. Amendments and Waivers.  Any term of this Warrant may be amended and the observance of any term of
this Warrant may be waived (either generally or in a particular instance and either retroactively or prospectively), with the written consent of the Company and GM. Any waiver or amendment effected in
accordance with this Section shall be binding upon GM, each holder of any Shares purchased under this Warrant at the time outstanding (including securities into which such Shares have been
converted), each future holder of all such Shares, and the Company. 

    16. Governing Law.  This Warrant shall be governed by the laws of the State of California as applied to
agreements among California residents made and to be performed entirely within the State of California. 

	

 	
 	

 	
 	

SEEBEYOND TECHNOLOGY CORPORATION
	

 	

 	

 	

 	

By:	

 	

/s/ JAMES DEMETRIADES     
 James Demetriades

Chief Executive Officer
	

 	

 	

Address:	

 	

404 E. Huntington Drive

Monrovia, CA 91016
	

 	

 	

 	

 	

Agreed to:
	

 	

 	

 	

 	

GENERAL MOTORS CORPORATION
	

 	

 	

 	

 	

By:	

 	

/s/ RALPH SZYGENDA     

	

 	
 	

 	
 	

Name:	
 	

Ralph Szygenda

	

 	
 	

 	
 	

Title:	
 	

Group Vice President and CIO

	

 	

 	

Address:	

 	

 	

 	

 

5

 
SUBSCRIPTION  

SeeBeyond
Technology Corporation

Attention: Corporate Secretary 

    The
undersigned hereby elects to purchase, pursuant to the provisions of the Warrant to Purchase Shares of Common Stock issued by SeeBeyond Technology Corporation and held by the
undersigned,                  shares of Common Stock of SeeBeyond Technology Corporation. 

    Payment
of the exercise price per share required under such Warrant accompanies this Subscription. 

    The
undersigned hereby represents and warrants that the undersigned is acquiring such shares for its own account for investment purposes only, and not for resale or with a view to
distribution of such shares or any part thereof. 

	 	 	 	 	WARRANTHOLDER:
	

 	
 	

 	
 	

GENERAL MOTORS CORPORATION
	

 	
 	

 	
 	

 	
 	

 
	

 	
 	

 	
 	

By:	
 	

 
	 	 	 	 	 	 	

	

 	
 	

 	
 	

Name:	
 	

 
	 	 	 	 	 	 	

	

 	
 	

 	
 	

Title:	
 	

 
	 	 	 	 	 	 	

	

 	
 	

 	
 	

 	
 	

 
	

 	
 	

Address:	
 	

 	
 	

	

 	
 	

 	
 	

 	
 	

	

 	
 	

 	
 	

 	
 	

	

Date:

	

Name in which shares should be registered:

6

QuickLinks

WARRANT PURCHASE AGREEMENT

EXHIBIT APrepared by MERRILL CORPORATION

QuickLinks
 -- Click here to rapidly navigate through this document
  

 
 

Exhibit 10.35    
  

EXECUTIVE CHANGE IN CONTROL

SEVERANCE BENEFITS AGREEMENT  

    This EXECUTIVE CHANGE IN CONTROL SEVERANCE BENEFITS AGREEMENT (the "Agreement") is entered into as of the
      day of            , 2001 (the "Effective Date"), between              ("Executive") and ONYX
PHARMACEUTICALS, INC. (the "Company"). This Agreement is intended to provide Executive with the compensation and benefits described herein upon the occurrence of
specific events. Certain capitalized terms used in this Agreement are defined in Article 5. 

    The
Company and Executive hereby agree as follows: 

ARTICLE 1
  SCOPE OF AND CONSIDERATION FOR THIS AGREEMENT

    1.1  Executive is currently employed by the Company. 

    1.2  The Company and Executive wish to set forth the compensation and benefits that Executive
shall be entitled to receive in the event of a Change in Control or upon certain terminations of employment occurring within thirteen (13) months following a Change in Control (each a "Covered
Termination"). 

    1.3  The duties and obligations of the Company to Executive under this Agreement shall be in
consideration for Executive's past services to the Company, Executive's continued employment with the Company, and, with respect to the benefits described in Article 2, Executive's execution of
a release in accordance with Section 3.1. 

    1.4  This Agreement shall supersede any other policy, plan, program or arrangement, including,
without limitation, a contract between Executive and any entity, relating to severance benefits payable by the Company to the Executive. 

ARTICLE 2
  CHANGE IN CONTROL BENEFITS AND SEVERANCE BENEFITS

    2.1  Change in Control Benefits.  A Change in Control
shall entitle Executive to receive the benefits provided in Article 2.7 with respect to a Change in Control. 

    2.2  Severance Benefits.  If Executive's employment
terminates due to an Involuntary Termination Without Cause or a Constructive Termination within thirteen (13) months following the effective date of a Change in Control, such termination of
employment will be deemed a Covered Termination. A Covered Termination shall entitle Executive to receive the following benefits set forth in Sections 2.3, 2.4, 2.5, 2.6 and 2.7. 

    2.3  Salary Continuation.  Executive shall continue to
receive Base Salary for [nine (9)] [eighteen (18)] months following a Covered Termination. Such amount
shall be paid in a lump sum and shall be subject to all required tax withholding. 

    2.4  Continued Health Insurance Benefits.  Provided that
Executive elects continued coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA"), the Company shall pay the portion of premiums of Executive's group medical, dental and
vision coverage, including coverage for Executive's eligible dependents, that the Company paid prior to the Covered Termination. The number of months of such premium payments shall equal the number of
months of salary continuation payments pursuant to Section 2.3 above, but in no event shall such premium payments be made for a period exceeding [nine
(9)/eighteen (18)] months or be made following the effective date of 

1

 

Executive's coverage by a medical, dental or vision insurance plan of a subsequent employer. Executive shall be required to notify the Company immediately if Executive becomes covered by a medical,
dental or vision insurance plan of a subsequent employer. 

    No
provision of this Agreement shall affect the continuation coverage rules under COBRA, except that the Company's payment of any applicable insurance premiums during the period of
salary continuation shall be credited as a payment by Executive for purposes of Executive's payment required under COBRA. Therefore, the period during which Executive must elect to continue the
Company's group medical coverage at Executive's own expense under COBRA, the length of time during which COBRA coverage will be made available to Executive, and all other rights and obligations of
Executive under COBRA (except the obligation to pay insurance premiums that the Company pays during the period of salary continuation) shall be applied in the same manner that such rules would apply
in the absence of this Agreement. At the conclusion of the period of salary continuation during which the Company will pay a portion of the premiums for Executive's group medical, dental and vision
coverage, Executive shall be responsible for the entire payment of premiums required under COBRA for the duration of the COBRA period. For purposes of this Section 2.4, applicable premiums that
will be paid by the Company shall not include any amounts payable by Executive under an Internal Revenue Code Section 125 health care reimbursement plan, which amounts, if any, are the sole
responsibility of Executive. 

    2.5  Continued Life Insurance Benefit.  The Company shall
pay the portion of the premiums of Executive's group life insurance coverage that the Company paid prior to the Covered Termination. The number of months of such premium payments shall be equal to the
number of months of salary continuation payments pursuant to Section 2.3 above, but in no event shall such premium payments be made for a period exceeding  [nine (9)/eighteen (18)] months or be made
following the effective date of Executive's coverage by a life insurance plan or
policy of a subsequent employer. Executive shall be required to notify the Company immediately if Executive becomes covered by a life insurance plan or policy of a subsequent employer. 

    2.6  Outplacement Services.  On behalf of Executive, the
Company shall pay for outplacement services for one year with an outplacement service provider selected by the Company; provided, however, that the total cost to the Company of such outplacement
services shall not exceed [fifteen thousand dollars ($15,000)/twenty five thousand dollars ($25,000)]. 

    2.7  Acceleration of Vesting.  Effective as of the date
of the Change in Control, the vesting and exercisability of fifty percent (50%) of the options to purchase the Company's Common Stock (or other stock awards granted by the Company) that are held by
Executive on such date shall be accelerated in full, and such options shall be exercisable by Executive for twelve (12) months following any subsequent termination of Executive's employment but
in case beyond the relevant expiration dates of such options. Such acceleration shall occur on a pro rata basis with respect to all outstanding stock awards, such that the accelerated vesting
percentage of shares that would otherwise vest at future vesting dates shall become immediately vested. Effective as of the date of a Covered Termination, the vesting and exercisability of all options
to purchase the Company's Common Stock (or other stock awards granted by the Company) that are held by Executive on such date shall be accelerated in full, and such options shall be exercisable by
Executive for twelve (12) months following such date. Notwithstanding the preceding provisions of this Section 2.7, if a Change in Control transaction is to be accounted for under the
"pooling of interests" accounting method pursuant to generally accepted accounting principles, and the acceleration of the vesting and exercisability of Executive's options (or other stock awards), as
provided for under this Section 2.7 with respect to such Change in Control transaction, would cause such Change in Control transaction to become ineligible to be accounted for as a "pooling of
interests" transaction, then such acceleration shall not occur. 

2

 

    2.8  Mitigation.  Except as otherwise specifically
provided herein, Executive shall not be required to mitigate damages or the amount of any payment provided under this Agreement by seeking other employment or otherwise, nor shall the amount of any
payment provided for under this Agreement be reduced by any compensation earned by Executive as a result of employment by another employer or by any retirement benefits received by Executive after the
date of a Covered Termination. 

ARTICLE 3
  LIMITATIONS AND CONDITIONS ON BENEFITS

    3.1  Release Prior to Payment of Benefits.  Upon the
occurrence of a Change in Control or a Covered Termination, and prior to the provision or payment of any benefits under this Agreement on account of such Change in Control or Covered Termination,
Executive shall execute a release in the form attached hereto and incorporated herein as, with respect to a Change in Control, Exhibit A and, with respect to a Covered Termination,
Exhibit B[, Exhibit C and Exhibit D], as applicable (each a "Release"). Such Release shall specifically
relate to all of Executive's rights and claims in existence at the time of such execution and shall confirm Executive's obligations under the Company's standard form of proprietary information and
inventions agreement. It is understood that, as specified in the applicable Release, Executive has a certain number of calendar days to consider whether to execute such Release. If Executive does not
execute such Release within the applicable period, no benefits shall be provided or payable under this Agreement pursuant to the Change in Control or Covered Termination, whichever is applicable. It
is further understood that if Executive is age 40 or older at the time of a Covered Termination, Executive may revoke the applicable Release within seven (7) calendar days after its execution.
If Executive revokes such Release within such subsequent seven (7) day period, no benefits shall be provided or payable under this Agreement pursuant to such Covered Termination. 

    3.2  Parachute Payments.  If any payment or benefit
Executive would receive in connection with a Change in Control from the Company or otherwise ("Payment") would (i) constitute a "parachute payment" within the meaning of Section 280G of
the Internal Revenue Code of 1986, as amended (the "Code"), and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the "Excise Tax"), then such
Payment shall be reduced to the Reduced Amount. The "Reduced Amount" shall be either (x) the largest portion of the Payment that would result in no portion of the Payment being subject to the
Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes,
income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive's receipt, on an after-tax basis, of the greater amount of the Payment
notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting "parachute payments" is necessary so that the Payment
equals the Reduced Amount, reduction shall occur in the following order unless Executive elects in writing a different order (provided, however, that
such election shall be subject to Company approval if made on or after the date
on which the event that triggers the Payment occurs): reduction of employee benefits; cancellation of accelerated vesting of stock awards; reduction of cash payments. In the event that acceleration of
vesting of stock award compensation is to be reduced, such acceleration of vesting shall be canceled in the reverse order of the date of grant of Executive's stock awards unless Executive elects in
writing a different order for cancellation. 

    The
accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the Change in Control shall perform the foregoing calculations. If
the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company shall appoint a nationally recognized
accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. 

3

 

    The accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and Executive within
fifteen (15) calendar days after the date on which Executive's right to a Payment is triggered (if requested at that time by the Company or Executive) or such other time as requested by the
Company or Executive. If the accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Amount, it shall furnish the
Company and Executive with an opinion reasonably acceptable to Executive that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made
hereunder shall be final, binding and conclusive upon the Company and Executive. 

    For
purposes of illustrating the intended operation of this Section 3.2, the following examples are provided: 

    Example 1:  Assume Executive's base amount calculated in accordance with Question and Answer 34 of Proposed Treasury
Regulation Section 1.280G-1 is $300,000. Assume further that upon a Covered Termination, Executive would receive $5,000 in health insurance benefits, $225,000 in severance payments,
and $674,000 in stock option acceleration valued in accordance with Question and Answer 24 of Proposed Treasury Regulation Section 1.280G-1. Assume further that Executive has a
marginal income tax rate of 50%. In this example, Executive's benefits payable pursuant to this Agreement have a value, for purposes of the 20% excise tax under Section 4999 of the Code, of
$904,000. Because $904,000 equals or exceeds three times Executive's base amount of $900,000, Executive is subject to the 20% excise tax under Section 4999 of the Code. In the absence of
Section 3.2 of this Agreement, upon receipt of the benefits described above, Executive would pay income tax on the severance payment equal to $112,500 (50% × $225,000)
and excise tax of $120,800 (20% × ($904,000 - $300,000)). (The excise tax is paid on the excess of the value of payments and benefits triggered by the
change in control less the Executive's base amount.) However, if effect were given to Section 3.2 of this Agreement, Executive's benefit would be cut back to provide Executive with greater
after tax benefits as follows: Instead of receiving $5,000 in health insurance benefits, Executive would receive $999 in health insurance benefits.
As a result of the reduction in health insurance benefits, Executive's benefits payable pursuant to this Agreement would have a value for excise tax purposes of $899,999, which would not equal or
exceed three times Executive's base amount and Executive would not be subject to the 20% excise tax. In this example, the $4,001 cut back of health insurance benefits payable to Executive saved
$120,800 in excise tax. 

    Example 2:  Assume the same facts as in Example 1, but the value of the severance payments due Executive is $700,000
instead of $225,000. In this example, Executive's benefits payable pursuant to this Agreement are valued for excise tax purposes at $1,379,000. Because $1,379,000 equals or exceeds three times
Executive's base amount of $900,000, Executive is subject to the 20% excise tax of $215,800 (20% × ($1,379,000 - $300,000)). If Executive's benefits were
cut back, Executive would avoid the $215,800 excise tax, but he would also forfeit $5,000 in health insurance benefits and $474,001 in severance payments. Pursuant to Section 3.2 of this
Agreement, Executive would receive all of the benefits payable under this Agreement and pay the excise tax because that will put him in a better after tax position. 

    3.3  Certain Reductions and Offsets.  To the extent that
any federal, state or local laws, including, without limitation, so-called "plant closing" laws, require the Company to give advance notice or make a payment of any kind to Executive
because of Executive's involuntary termination due to a layoff, reduction in force, plant or facility closing, sale of business, change in control, or any other similar event or reason, the benefits
payable under this Agreement shall be correspondingly reduced. The benefits provided under this Agreement are intended to satisfy any and all statutory obligations that may arise out of Executive's
involuntary termination of employment for the foregoing reasons, and the parties shall so construe and enforce the terms of the Agreement. 

4

 
ARTICLE 4
  OTHER RIGHTS AND BENEFITS

    Nothing
in the Agreement shall prevent or limit Executive's continuing or future participation in any benefit, bonus, incentive or other plans, programs, policies or practices
provided by the Company and for which Executive may otherwise qualify, nor shall anything herein limit or otherwise affect such rights as Executive may have under other agreements with the Company
except as provided in Section 1.4 above. Except as otherwise expressly provided herein, amounts that are vested benefits or that Executive is otherwise entitled to receive under any plan,
policy, practice or program of the Company at or subsequent to the date of a Change in Control shall be payable in accordance with such plan, policy, practice or program. 

ARTICLE 5
  DEFINITIONS

    For
purposes of the Agreement, the following terms are defined as follows: 

    5.1  "Base Salary" means Executive's annual base salary
as in effect during the last regularly scheduled payroll period immediately preceding the effective date of the Change in Control or as increased thereafter. 

    5.2  "Board" means the Board of Directors of the Company. 

    5.3  "Change in Control" means one or more of the
following events: 

    (a) There is consummated a sale or other disposition of all or substantially of assets of the Company (other than a sale
to an entity where at least fifty percent (50%) of the combined voting power of the voting securities of such entity are owned by the stockholders of the Company in substantially the same proportions
as their ownership of the Company immediately prior to such sale). 

    (b) Any person, entity or group (other than the Company, a subsidiary or affiliate of the Company, or a Company employee
benefit plan, including any trustee of such plan acting as trustee) becomes the beneficial owner, directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the
combined voting power of the Company's then outstanding securities other than by virtue of a merger, consolidation or similar transaction. 

    (c) There is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company
and, immediately after the consummation of such transaction, the stockholders immediately prior to the consummation of such transaction do not own, directly or indirectly, outstanding voting
securities representing more than fifty percent (50%) of the combined outstanding voting power of the surviving entity in such transaction or more than fifty percent (50%) of the combined outstanding
voting power of the parent of the surviving entity in such transaction. 

    5.4  "Company" means Onyx Pharmaceuticals, Inc.
or, following a Change in Control, the surviving entity resulting from such transaction, or any subsequent surviving entity resulting from any subsequent Change in Control. 

    5.5  "Constructive Termination" means that Executive
voluntarily terminates employment after one of the following is undertaken without Executive's express written consent: 

    (a) the assignment to Executive of duties or responsibilities that results in a material diminution in Executive's
function as in effect immediately prior to the effective date of the Change in Control; 

5

 

    (b) a reduction in Executive's Base Salary, unless the reduction is made pursuant to an
across-the-board reduction of the base salaries of all executive officers of the Company of no more than ten percent (10%); 

    (c) a change in Executive's business location of more than fifteen (15) miles from the business location
immediately prior to the effective date of the Change in Control; 

    (d) a material breach by the Company of any provision of this Agreement; or 

    (e) any failure by the Company to obtain the assumption of this Agreement by any successor or assign of the Company,
such assumption to be effective no later than the effective date of a Change in Control. 

    5.6  "Covered Termination" means an Involuntary
Termination Without Cause or a Constructive Termination, either of which occurs within thirteen (13) months following the effective date of a Change in Control. 

    5.7  "Involuntary Termination Without Cause" means
Executive's dismissal or discharge for reasons other than Cause. For this purpose, "Cause" means that, in the reasonable determination of the Company, Executive (i) has committed an intentional
act or acted with gross negligence that has materially injured the business of the Company; (ii) has intentionally refused or failed to follow lawful and reasonable directions of the Board or
the appropriate individual to whom Executive reports; (iii) has willfully and habitually neglected Executive's duties for the Company; or (iv) has been convicted of a felony involving
moral turpitude that is likely to inflict or has inflicted material injury on the business of the Company. Notwithstanding the foregoing, Cause shall not exist based on conduct described in
clause (ii) or (iii) unless the conduct described in such clause has not been cured within fifteen (15) days following Executive's receipt of written notice from the Company
specifying the particulars of the conduct constituting Cause. 

ARTICLE 6
  GENERAL PROVISIONS

    6.1  Employment Status.  This Agreement does not
constitute a contract of employment or impose upon Executive any obligation to remain as an employee, or impose on the Company any obligation (i) to retain Executive as an employee,
(ii) to change the status of Executive as an at-will employee or (iii) to change the Company's policies regarding termination of employment. 

    6.2  Notices.  Any notices provided hereunder must be in
writing, and such notices or any other written communication shall be deemed effective upon the earlier of personal delivery (including personal delivery by facsimile) or the third day after mailing
by first class mail, to the Company at its primary office location and to Executive at Executive's address as listed in the Company's payroll records. Any payments made by the Company to Executive
under the terms of this Agreement shall be delivered to Executive either in person or at the address as listed in the Company's payroll records. 

    6.3  Severability.  Whenever possible, each provision of
this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any
respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be
reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provisions had never been contained herein. 

    6.4  Waiver.  If either party should waive any breach of
any provisions of this Agreement, he or it shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement. 

6

 

    6.5  Arbitration.  Unless otherwise prohibited by law or
specified below, all disputes, claims and causes of action, in law or equity, arising from or relating to this Agreement or its enforcement, performance, breach, or interpretation shall be resolved
solely and exclusively by final and binding arbitration held in the San Francisco Bay Area through Judicial Arbitration & Mediation Services/Endispute ("JAMS") under the then existing JAMS
employment law arbitration rules. However, nothing in this Section 6.5 is intended to prevent either party from obtaining injunctive relief in court to prevent irreparable harm pending the
conclusion of any such arbitration. Each party in any such arbitration shall be responsible for its own attorneys' fees, costs and necessary disbursement; provided,
however, that in the event one
party refuses to arbitrate and the other party seeks to compel arbitration by court order, if such other party prevails, it shall be entitled to recover reasonable attorneys' fees, costs and necessary
disbursements. Pursuant to California Civil Code Section 1717, each party warrants that it was represented by counsel in the negotiation and execution of this Agreement, including the
attorneys' fees provision herein. 

    6.6  Complete Agreement.  This Agreement, including
Exhibit A, Exhibit B and Exhibit C, constitutes the entire agreement between Executive and the Company and is the complete, final, and exclusive embodiment of their agreement with
regard to this subject matter, wholly superseding all written and oral agreements with respect to payments and benefits to Executive in the event of employment termination. It is entered into without
reliance on any promise or representation other than those expressly contained herein. 

    6.7  Amendment or Termination of Agreement; Continuation of
Agreement.  This Agreement may be changed or terminated only upon the mutual written consent of the Company and Executive. The written consent of the Company to
a change or termination of this Agreement must be signed by an executive officer of the Company (other than Executive) after such change or termination has been approved by the Board. Unless so
terminated, this Agreement shall continue in effect for as long as Executive continues to be employed by the Company or by any surviving entity following any Change in Control. In other words, if,
following a Change in Control, the Executive continues to be employed by the surviving entity without a Covered Termination and the surviving entity then undergoes a Change in Control, following which
Executive is terminated by the subsequent surviving entity in a Covered Termination, then Executive shall receive the benefits described in Section 2 hereof. 

    6.8  Counterparts.  This Agreement may be executed in
separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement. 

    6.9  Headings.  The headings of the Articles and Sections
hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof. 

    6.10  Successors and Assigns.  This Agreement is intended
to bind and inure to the benefit of and be enforceable by Executive, and the Company, and any surviving entity resulting from a Change in Control and upon any other person who is a successor by
merger, acquisition, consolidation or otherwise to the business formerly carried on by the Company, and their respective successors, assigns, heirs, executors and administrators, without regard to
whether or not such person actively assumes any rights or duties hereunder; provided, however, that Executive may not assign any duties hereunder and
may not assign any rights hereunder without the written consent of the Company, which consent shall not be withheld unreasonably. 

    6.11  Choice of Law.  All questions concerning the
construction, validity and interpretation of this Agreement will be governed by the law of the State of California, without regard to such state's conflict of laws rules. 

7

 

    6.12  Non-Publication.  The parties mutually
agree not to disclose publicly the terms of this Agreement except to the extent that disclosure is mandated by applicable law or to respective advisors
(e.g., attorneys, accountants). 

    6.13  Construction of Agreement.  In the event of a
conflict between the text of the Agreement and any summary, description or other information regarding the Agreement, the text of the Agreement shall control. 

    IN WITNESS WHEREOF, the parties have executed this Agreement on the Effective Date written above. 

	

 	
 	

 	
 	

 
	ONYX PHARMACEUTICALS, INC.	 	[EXECUTIVE]
	

 	
 	

 	
 	

 
	

By:	
 	

 	
 	

 
	 	 	
	 	

	Name:	 	 
	Title:	 	 
	

	
 	

 	
 	

 

8

 

	Exhibit A:	 	Release (Change in Control)
	Exhibit B:	 	Release (Individual Termination—Age 40 or Older)
	Exhibit C:	 	Release (Individual and Group Termination—Under Age 40)
	Exhibit D:	 	Release (Group Termination—Age 40 or Older)

9

   EXHIBIT A

RELEASE
  (CHANGE IN CONTROL)

    Certain
capitalized terms used in this Release are defined in the Executive Severance Benefits Agreement (the "Agreement") which I have executed and of which this Release is a part. 

    I
hereby confirm my obligations under the Company's proprietary information and inventions agreement. 

    I
acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: "A general release does not extend to
claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially affected his settlement with the
debtor." I hereby expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my release of any
claims I may have against the Company. 

    Except
as otherwise set forth in this Release, I hereby release, acquit and forever discharge the Company, its parents and subsidiaries, and their officers, directors, agents,
servants, employees, shareholders, successors, assigns and affiliates, of and from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys fees, damages, indemnities and
obligations of every kind and nature, in law, equity, or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed (other than any claim for indemnification I may have as a
result of any third party action against me based on my employment with the Company), arising out of or in any way related to agreements, events, acts or conduct at any time prior to the date I
execute this Release, including, but not limited to: all such claims and demands directly or indirectly arising out of or in any way connected with my employment with the Company or the termination of
that employment, including but not limited to, claims of intentional and negligent infliction of emotional distress, any and all tort claims for personal injury, claims or demands related to salary,
bonuses, commissions, stock, stock options, or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other form of compensation;
claims pursuant to any federal, state or local law or cause of action including, but not limited to, the federal Civil Rights Act of 1964, as amended; the federal Age Discrimination in Employment Act
of 1967, as amended ("ADEA"); the federal Employee Retirement Income Security Act of 1974, as amended; the federal Americans with Disabilities Act of 1990; the California Fair Employment and Housing
Act, as amended; tort law; contract law; wrongful discharge; discrimination; fraud; defamation; emotional distress; and breach of the implied covenant of good faith and fair dealing;  provided, however,
that nothing in this paragraph shall be construed in any
way to release the Company from its obligation to indemnify me pursuant to the Company's indemnification obligation pursuant to agreement or applicable law. 

    I
also acknowledge that I am knowingly and voluntarily waiving and releasing any right I may have under the ADEA. I also acknowledge that the consideration given under the Agreement
for the waiver and release in the preceding paragraph hereof is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing that:
(A) my waiver and release do not apply to any rights or claims that may arise on or after the date I execute this Release; (B) I have the right to consult with an attorney prior to
executing this Release; and (C) I have twenty-one (21) days to consider this Release (although I may choose to voluntarily execute this Release earlier). 

	 	[EXECUTIVE]
	

 	

 	
 	

 
	 	

	

 	

Date:	
 	

 
	 	 	 	

10

   EXHIBIT B

RELEASE
  (INDIVIDUAL TERMINATION—AGE 40 OR OLDER)

    Certain
capitalized terms used in this Release are defined in the Executive Severance Benefits Agreement (the "Agreement") which I have executed and of which this Release is a part. 

    I
hereby confirm my obligations under the Company's proprietary information and inventions agreement. 

    I
acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: "A general release does not extend to
claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially affected his settlement with the
debtor." I hereby expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my release of any
claims I may have against the Company. 

    Except
as otherwise set forth in this Release, I hereby release, acquit and forever discharge the Company, its parents and subsidiaries, and their officers, directors, agents,
servants, employees, shareholders, successors, assigns and affiliates, of and from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys fees, damages, indemnities and
obligations of every kind and nature, in law, equity, or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed (other than any claim for indemnification I may have as a
result of any third party action against me based on my employment with the Company), arising out of or in any way related to agreements, events, acts or conduct at any time prior to the date I
execute this Release, including, but not limited to: all such claims and demands directly or indirectly arising out of or in any way connected with my employment with the Company or the termination of
that employment, including but not limited to, claims of intentional and negligent infliction of emotional distress, any and all tort claims for personal injury, claims or demands related to salary,
bonuses, commissions, stock, stock options, or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other form of compensation;
claims pursuant to any federal, state or local law or cause of action including, but not limited to, the federal Civil Rights Act of 1964, as amended; the federal Age Discrimination in Employment Act
of 1967, as amended ("ADEA"); the federal Employee Retirement Income Security Act of 1974, as amended; the federal Americans with Disabilities Act of 1990; the California Fair Employment and Housing
Act, as amended; tort law; contract law; wrongful discharge; discrimination; fraud; defamation; emotional distress; and breach of the implied covenant of good faith and fair dealing;  provided, however,
that nothing in this paragraph shall be construed in any
way to release the Company from its obligation to indemnify me pursuant to the Company's indemnification obligation pursuant to agreement or applicable law. 

    I
acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under ADEA. I also acknowledge that the consideration given under the Agreement for the
waiver and release in the preceding paragraph hereof is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing, as required by
the ADEA, that: (A) my waiver and release do not apply to any rights or claims that may arise on or after the date I execute this Release; (B) I have the right to consult with an
attorney prior to executing this Release; (C) I have twenty-one (21) days to consider this Release (although I may choose to voluntarily execute this Release earlier);
(D) I have seven (7) days following my execution of this Release to revoke the Release; and (E) this Release shall not be effective until the date upon which the revocation period
has expired, which shall be the eighth (8th) day after I execute this Release. 

	 	[EXECUTIVE]
	

 	

 	
 	

 
	 	

	

 	

Date:	
 	

 
	 	 	 	

11

   EXHIBIT C

RELEASE
  (INDIVIDUAL AND GROUP TERMINATION—UNDER AGE 40)

    Certain
capitalized terms used in this Release are defined in the Executive Severance Benefits Agreement (the "Agreement") which I have executed and of which this Release is a part. 

    I
hereby confirm my obligations under the Company's proprietary information and inventions agreement. 

    I
acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: "A general release does not extend to
claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially affected his settlement with the
debtor." I hereby expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my release of any
claims I may have against the Company. 

    Except
as otherwise set forth in this Release, I hereby release, acquit and forever discharge the Company, its parents and subsidiaries, and their officers, directors, agents,
servants, employees, shareholders, successors, assigns and affiliates, of and from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys fees, damages, indemnities and
obligations of every kind and nature, in law, equity, or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed (other than any claim for indemnification I may have as a
result of any third party action against me based on my employment with the Company), arising out of or in any way related to agreements, events, acts or conduct at any time prior to the date I
execute this Release, including, but not limited to: all such claims and demands directly or indirectly arising out of or in any way connected with my employment with the Company or the termination of
that employment, including but not limited to, claims of intentional and negligent infliction of emotional distress, any and all tort claims for personal injury, claims or demands related to salary,
bonuses, commissions, stock, stock options, or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other form of compensation;
claims pursuant to any federal, state or local law or cause of action including, but not limited to, the federal Civil Rights Act of 1964, as amended; the federal Employee Retirement Income Security
Act of 1974, as amended; the federal Americans with Disabilities Act of 1990; the California Fair Employment and Housing Act, as amended; tort law; contract law; wrongful discharge; discrimination;
fraud; defamation; emotional distress; and breach of the implied covenant of good faith and fair dealing; provided, however, that nothing in this
paragraph shall be construed in any way to release the Company from its obligation to indemnify me pursuant to the Company's indemnification obligation pursuant to agreement or applicable law. 

    I
acknowledge that the consideration given under the Agreement for the waiver and release in the preceding paragraph hereof is in addition to anything of value to which I was already
entitled. I further acknowledge that I have been advised by this writing that: (A) my waiver and release do not apply to any rights or claims that may arise on or after the date I execute this
Release; (B) I have the right to consult with an attorney prior to executing this Release; and (C) I have twenty-one (21) days to consider this Release (although I may
choose to voluntarily execute this Release earlier). 

	 	[EXECUTIVE]
	

 	

 	
 	

 
	 	

	

 	

Date:	
 	

 
	 	 	 	

12

   EXHIBIT D

RELEASE
  (GROUP TERMINATION—AGE 40 OR OLDER)

    Certain
capitalized terms used in this Release are defined in the Executive Severance Benefits Agreement (the "Agreement") which I have executed and of which this Release is a part. 

    I
hereby confirm my obligations under the Company's proprietary information and inventions agreement. 

    I
acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: "A general release does not extend to
claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially affected his settlement with the
debtor." I hereby expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my release of any
claims I may have against the Company. 

    Except
as otherwise set forth in this Release, I hereby release, acquit and forever discharge the Company, its parents and subsidiaries, and their officers, directors, agents,
servants, employees, shareholders, successors, assigns and affiliates, of and from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys fees, damages, indemnities and
obligations of every kind and nature, in law, equity, or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed (other than any claim for indemnification I may have as a
result of any third party action against me based on my employment with the Company), arising out of or in any way related to agreements, events, acts or conduct at any time prior to the date I
execute this Release, including, but not limited to: all such claims and demands directly or indirectly arising out of or in any way connected with my employment with the Company or the termination of
that employment, including but not limited to, claims of intentional and negligent infliction of emotional distress, any and all tort claims for personal injury, claims or demands related to salary,
bonuses, commissions, stock, stock options, or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other form of compensation;
claims pursuant to any federal, state or local law or cause of action including, but not limited to, the federal Civil Rights Act of 1964, as amended; the federal Age Discrimination in Employment Act
of 1967, as amended ("ADEA"); the federal Employee Retirement Income Security Act of 1974, as amended; the federal Americans with Disabilities Act of 1990; the California Fair Employment and Housing
Act, as amended; tort law; contract law; wrongful discharge; discrimination; fraud; defamation; emotional distress; and breach of the implied covenant of good faith and fair dealing;  provided, however,
that nothing in this paragraph shall be construed in any way to release the Company from its obligation to indemnify me pursuant to
the Company's indemnification obligation pursuant to agreement or applicable law. 

    I
acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under the ADEA. I also acknowledge that the consideration given under the Agreement for
the waiver and release in the preceding paragraph hereof is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing, as
required by the ADEA, that: (A) my waiver and release do not apply to any rights or claims that may arise on or after the date I execute this Release; (B) I have the right to consult
with an attorney prior to executing this Release; (C) I have forty-five (45) days to consider this Release (although I may choose to voluntarily execute this Release
earlier); (D) I have seven (7) days following my execution of this Release to revoke the Release; (E) this Release shall not be effective until the date upon which the revocation
period has expired, which shall be the eighth day (8th) after I execute this Release; and (F) I have received with this Release a detailed list of the job titles and ages of all employees who
were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated. 

	 	[EXECUTIVE]
	

 	

 	
 	

 
	 	

	

 	

Date:	
 	

 
	 	 	 	

13

QuickLinks

Exhibit 10.35

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}]]